GlassScriptPhysician profile
Akira Nishikawa
NPI 1588695019
$109,283.57
in general payments reported to CMS, 2019-2025
35 companies · $978 in 2025
The $978 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $36K · 2021: $1,406 · 2022: $3,206 · 2023: $1,740 · 2024: $1,802 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,520.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shimadzu Precision Instruments, INC. | $96,182.40 | 2019-2020 | |
| Abbott Laboratories | $4,991.23 | 2019-2025 | Cardiomems, Advisor, Agilis Hispro |
| Boston Scientific Corporation | $2,035.56 | 2019-2025 | Synergy, Accolade Sr, Farapulse |
| Cardiovascular Systems INC. | $898.29 | 2019 | |
| Amgen INC. | $788.59 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $662.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $557.06 | 2020-2025 | Wainua, Farxiga |
| Teleflex LLC | $532.04 | 2019-2024 | Raider, Guideliner, Supercross |
| Novartis Pharmaceuticals Corporation | $531.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $419.56 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $365.88 | 2021-2025 | Camzyos, Eliquis |
| Acutus Medical, INC. | $134.64 | 2019 | |
| Janssen Scientific Affairs, LLC | $131.64 | 2022 | |
| Medtronic, INC. | $124.92 | 2024 | Hawkone |
| Biotronik INC. | $113.60 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $104.68 | 2019-2021 | |
| Esperion Therapeutics, INC. | $97.69 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $89.58 | 2023 | Amvuttra |
| Bridgebio Pharma, INC. | $65.47 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $49.29 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $47.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.00 | 2022 | |
| Tactile Systems Technology INC | $42.91 | 2024 | Entre Plus, Flexitouch Plus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2021-2023 | Jardiance |
| Impulse Dynamics (USA) INC. | $29.68 | 2021 | |
| Novo Nordisk INC | $22.65 | 2022 | |
| Altathera Pharmaceuticals LLC | $21.77 | 2022 | |
| Grifols USA, LLC | $21.12 | 2023 | Prolastin-C Liquid |
| Scpharmaceuticals INC. | $19.99 | 2025 | |
| Cvrx, INC. | $18.21 | 2021 | |
| Irhythm Technologies, INC. | $16.63 | 2024 | Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $16.32 | 2023 | Arcalyst |
| Biosense Webster, INC. | $15.61 | 2023 | Carto 3 |
| Ge Healthcare | $14.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akira Nishikawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.